Anxiety in women is not only psychological. The hormonal fluctuations that happen across the menstrual cycle, during perimenopause, after childbirth, and at other reproductive transitions directly affect the neurochemical systems that regulate anxiety. If your anxiety follows a predictable pattern across the month, spikes at specific life stages, or feels qualitatively different from anxiety that others describe, hormones may be a significant driver.
This is not a soft claim. Oestrogen directly modulates serotonin and GABA receptors. Progesterone metabolises into a compound called allopregnanolone that acts on the same brain receptors as benzodiazepines. When these hormones drop, the anxiolytic effect they were providing disappears, and anxiety rises.
Oestrogen has receptors throughout the brain, including in the amygdala, hippocampus, and prefrontal cortex: exactly the regions that regulate the anxiety response. When oestrogen levels are adequate, it supports the production and activity of serotonin, which has mood-stabilising and anxiolytic effects, and enhances GABA receptor sensitivity, which is the primary inhibitory neurotransmitter system. Higher oestrogen generally means more natural anxiety dampening. Lower oestrogen means less of this biochemical cushioning.
This is why the follicular phase, when oestrogen is rising toward its peak, tends to feel psychologically easier for many women. It is not optimism. It is neurochemistry.
In the week before menstruation, both oestrogen and progesterone drop sharply. The drop in progesterone matters because progesterone metabolises into allopregnanolone, which acts on GABA-A receptors in a way that is pharmacologically similar to benzodiazepines. When progesterone drops, so does allopregnanolone, and the natural calming effect it was providing disappears. The result is a neurochemical withdrawal from the brain's own anti-anxiety compound, which produces irritability, tension, sleep disruption, and heightened anxiety that many women experience as PMS.
For women with PMDD (premenstrual dysphoric disorder), this withdrawal produces severe anxiety, depression, and emotional dysregulation that is clinically distinct from PMS. PMDD is a recognised diagnostic entity that responds to specific treatments including SSRIs taken only in the luteal phase, not simply lifestyle adjustment.
Perimenopause, the transition period before menstruation stops, typically begins in the mid-to-late forties and can last several years. Oestrogen during this phase does not simply decline steadily. It fluctuates erratically, spiking and dropping in unpredictable patterns. These fluctuations, rather than simply low oestrogen levels, appear to be the primary driver of perimenopausal anxiety.
Many women experiencing new or dramatically worsened anxiety in their forties do not connect it to perimenopause, partly because they are still menstruating and partly because perimenopause is underdiagnosed and underrepresented in public health information. If anxiety has significantly changed in character or intensity during the perimenopause years without a clear psychological cause, hormonal evaluation is warranted.
After childbirth, the dramatic withdrawal of pregnancy hormones, oestrogen and progesterone drop to their lowest levels in years within days of delivery, produces a neurochemical environment that is highly vulnerability-generating. Postpartum anxiety is at least as common as postpartum depression and often coexists with it, but receives considerably less public recognition. It manifests as excessive worry about the baby, difficulty sleeping even when the baby sleeps, physical tension, and a constant sense of dread or danger.
Postpartum anxiety is a medical condition, not a failure of maternal adjustment, and it responds well to treatment including therapy and, when indicated, medication that is compatible with breastfeeding.
Cycle tracking is the most valuable first step: logging anxiety levels daily alongside cycle phase creates the pattern evidence needed to understand your own hormonal sensitivity. Apps that track both mood and cycle can make this visible within two to three months. This data is also useful for any clinician you consult.
For premenstrual anxiety specifically, strategies that reduce the impact of the hormonal withdrawal include regular aerobic exercise, which has measurable effects on GABA and serotonin, and dietary approaches that support stable blood sugar across the luteal phase. For perimenopause, hormone replacement therapy (HRT) has evidence for reducing anxiety in addition to physical symptoms and is worth discussing with a gynaecologist or menopause specialist.
CBT remains effective for anxiety regardless of its hormonal component because it changes the anxiety system's reactivity to the physiological fluctuations. The hormonal changes produce the initial anxiety signal, but cognitive patterns, avoidance behaviours, and catastrophising determine how much that signal amplifies. Treating both the hormonal and the psychological component produces better outcomes than treating either alone.
"If your anxiety follows the same pattern every month, it is not a coincidence. It is your neurochemistry responding to hormonal fluctuations that are measurable, predictable, and treatable."